The Disappointing Reality of Crowdfunding Cancer Care
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Prostate Cancer
PROSTATE ADVISOR
FEATURED CONTENT
-
-
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed. -
Pathologists Need Better Reporting Guidelines for Postneoadjuvant Chemotherapy Specimens
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment. -
Cognitive Impairment Following Immunotherapy Treatment May Be Underestimated
As more and more patients undergo immunotherapy treatments, understanding possible side effects on cognitive function is an important research gap. -
Microbiome Analysis May Be a Feasible Diagnostic Test for Prostate Cancer
The microbiome could have a role in the diagnosis of PrCa.
Current Research Into Pain Assessment
Immunotherapy for Prostate Cancer
Targeted Agents
Targeted Agents (cont.)
Radium-223
Chemotherapy
Immunotherapy
Treatment Sequencing
Androgen Deprivation Therapy
Duration of ADT
Docetaxel in Combination With ADT
HSD3B1 Allele Inheritance Linked With ADT Resistance
ADT and Radiation
Predictions for the Future
PROSTATE CANCER NEWS
Apalutamide Plus ADT for mCSPC Maintains Health-Related Quality of Life
Long-Term Antiandrogen Therapy With Salvage Radiation May Up Death Risk
Radiation Therapy After Prostate Surgery Offers No Benefit
Kegel Exercises May Prevent Incontinence Associated With Prostate Cancer
Upfront Antiandrogens, Chemotherapy for mCRPC Offer Similar Survival
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
